Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LYNK-003: Olaparib ± Bevacizumab vs Bevacizumab + Fluoropyrimidine in Metastatic Colorectal Cancer Maintenance
jRCT2031200146Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of olaparib, bevacizumab, fluorouracil and capecitabine in colorectal cancer (CRC) (3 arms), sponsored by Merck & Co. Primary endpoint: Progression-free Survival (PFS) by BICR using RECIST 1.1. Started Oct 2020; status: completed.
02
Drugs
olaparibbevacizumabfluorouracilcapecitabine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT2031200146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200146.